PROFUSA INC (PFSA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.72+3.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Manage financial obligations and capital allocation: 1-for-4 reverse split vs no dilution target.
Profusa aims to complete the acquisition of Bio Insights PanOmics assets to grow its product line. The company is actively managing financial obligations to stabilize its position. It is working to address Nasdaq listing compliance to maintain market presence. These steps could enable a recovery from current losses.
Profusa is loss-making with no revenue expected in 2026. It faces ongoing Nasdaq compliance issues and financial instability. The company’s valuation has fallen sharply, reflecting high risk and uncertain recovery.
The market prices in a steep decline with implied growth rates of -22.6% over 3 years and -14.3% over 5 years. Our view aligns with this cautious outlook given the lack of revenue and ongoing challenges.
Breaks if: acquisition not completed by end of 2026
Breaks if: significant new debt or equity dilution beyond current plans in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
PFSA represents a speculative growth investment. The company is in a volatile state with mixed management execution and elevated risk, but it has shown strong recent financial performance.
The market appears to price in a low level of fragility, suggesting that investors may not expect significant disruptions. PFSA is currently viewed as cheap compared to its peers, but the low model confidence indicates uncertainty in future performance.
Management is focused on acquiring commercial-stage diagnostics companies and maintaining Nasdaq compliance, with mixed progress on these priorities. Recent financial performance has improved, but the company remains loss-making, which adds to the uncertainty.
The future trajectory of PFSA will depend on broader sector performance, particularly the results of major healthcare companies like ABT, MDT, and SYK. Additionally, the company's ability to successfully integrate acquisitions and manage financial obligations will be crucial.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: failure to meet Nasdaq compliance milestones by end of 2026
Over the next 1 to 3 years, PFSA's outlook remains uncertain due to its volatility and reliance on sector trends. Not investment advice.